We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies inc. About Theratechnologies. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. Apr 14, 2020, 8:30 a. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. 2 million. Phone Number (514) 336-7800. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. We also use them to share usage. com. Track Theratechnologies Inc. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. European Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Investor inquiries: Elif McDonald. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. com uses cookies on this site. MONTREAL, Oct. Cookies are used to offer you a better browsing experience and to analyze our. com uses cookies on this site. These companies provide a lot of detail to the OTC Markets Group including audited financials. TORONTO, Sept. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. 74M. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. stockhouse. The business had revenue of $27. The company reported ($0. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. By continuing to use our service, you agree to our use of cookies. TH | May 19, 2023. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. : Renegotiated Lease to Generate Substantial Annual Savings. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 0. Montréal, Québec, Canada . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Stockhouse. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Headquarters. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. TH | September 5, 2023. The abstracts are now available at aacr. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Theratechnologies inc. Theratechnologies Announces 1-for-4 Reverse Stock Split. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Stockhouse. is a pharmaceutical company. Find the latest Theratechnologies Inc. (THTX) Stock Price, Quote & News - Stock Analysis -20. Theratechnologies had a negative net margin of 36. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FAQ – Utilisateurs de TMX Argent NOUVEAU. . 02%. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. Cookies are used to offer you a better browsing experience and to. is an employee of TaiMed Biologics USA, Inc. 05M. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. Theratechnologies Inc. Theratechnologies, Inc. One reason for that is that this tier does not include penny stocks. 514-336-7800. Follow. (882) posted 3 minutes ago. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. (2013-04-03 | TSX:TH) Theratechnologies Inc. MONTREAL, Oct. W. Stockhouse. 39 50-Day Range $0. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. com uses cookies on this site. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. MONTREAL, Feb. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Phone Number 15143319691. com uses cookies on this site. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. See a list of the most recent Stock Forum posts on Stockhouse. com uses cookies on this site. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. com uses cookies on this site. MONTREAL, Nov. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. Theratechnologies, Inc. S. We also use them to share usage. Stockhouse. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. 1300 (+9. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. Stockhouse. This news release constitutes a "designated news release" for the purposes of. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Investor Relations. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. We also use them to share usage information with our partners. FAQ – Émetteurs inscrits NOUVEAU. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. 63. By continuing to use our service, you agree to our use of cookies. Stockhouse. Further. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. On average, they expect the company's stock price to reach $36. com uses cookies on this site. 89 $2. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 6. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. com uses cookies on this site. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Sept. 23 to a day high of $1. 521. $44. 23) diluted earnings per. 25. 5000 +0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. L. 8. Theratechnologies Inc. Who is Theratechnologies. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Company Type For Profit. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. com uses cookies on this site. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage. The company had revenue of $20. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. We also use them to share usage information with our partners. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. - Q3 2022 Consolidated. Stockhouse. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Forecast to breakeven in 2024 Jul 15. com. Conjugating the short peptide with various anti-cancer agents allows for. By continuing to use our service, you agree to our use of cookies. 10% least volatile stocks in CA Market. If you have HIV, it's important to know the difference. 49%) At close: 04:00PM EST 1. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. : 001-35203 Mr. By continuing to use our service, you agree to our use of cookies. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 38. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies (THTX) Stock Price, News & Analysis $1. Theratechnologies Inc. Theratechnologies Inc. Theratechnologies Inc. 75%. Cookies are used to offer you a better browsing experience and to analyze our traffic. . Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Trogarzo® and. Theratechnologies layoffs. Further. This news release constitutes a “designated news release” for the purposes of the Company’s. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. THTX earnings call for the period ending February 29, 2020. 8 million. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. About SORT1+ Technology™ and TH1902. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. (Image via Theralase Technologies Inc. Unveiling Silvercorp's golden potential at the Ying Mining District. 9 million, adjusted EBITDA of $2. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. MONTREAL, Sept. For investor inquiries: Leah Gibson. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. 24 million, 48. - Cash, bonds and money market funds of US$22. T. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. [email protected] Inc: Overview. S. RESSOURCES. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. View analysts price targets for THTX. View Company Info for Free. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. We also use them to share usage. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. By continuing to use our service, you agree to our use of cookies. This suggests a possible upside of 2,471. com uses cookies on this site. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. NCU. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. We also use them to share usage information with our partners. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. THERATECHNOLOGIES INC. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Cookies are used to offer you a better browsing experience and to analyze our traffic. -based clinical sites participating in the conduct of the Phase. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. MONTREAL, Oct. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. 81 million for the quarter. MONTREAL, Nov. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Contact Email communications@theratech. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to. 1-438. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. m. Heures de négociation. . Senior Director, Investor Relations. com uses cookies on this site. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. stock news by MarketWatch. 4% from the stock's current price. 4% annually. 40%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. When this page refreshes you will be logged in with the new address. The reported ($0. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . " The 12-month stock price forecast is $18. Revenues have been growing at an average rate of 10. 20% from a day low at $1. com uses cookies on this site. 23) earnings per share over the last year ( ($1. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Stockhouse. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. TH | March 7, 2023. stock news by MarketWatch. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Statut du système de négociation. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Montréal, Québec, Canada . $103. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Visit the TSX ETF Investor Centre to access our screener and comparison tool. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Betteryear2. 89 52. TH | September 5, 2023. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. US Headquarters. com uses cookies on this site. It is the Company’s proprietary peptide linked to. The company was. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. com. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. During the last trading day the stock fluctuated 12. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. 5% workforce reduction. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies inc. Stockhouse. La Bourse de Toronto a perdu. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. 33. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Stockhouse. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. 35 as of 10:41 a. 's motion for leave to commence. Stockhouse. Further. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. By continuing to use our service, you agree to our use of cookies. Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. 17% from a day low at $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. By continuing to use our service, you agree to our use of cookies. Shares of Theratechnologies are up 4. Theratechnologies Inc. . MONTREAL, Feb. 04) earnings per share (EPS) for the quarter. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | February 28, 2023. Their THTX share price targets range from $36. com. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. TH | October 13, 2022. $30. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. There are 102 news items for this page. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study.